230 related articles for article (PubMed ID: 26451276)
1. Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity.
Zhang Y; Hochster H; Stein S; Lacy J
Exp Hematol Oncol; 2015; 4():29. PubMed ID: 26451276
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis.
Chae H; Jeong H; Cheon J; Chon HJ; Ryu H; Kim IH; Kang MJ; Jeong JH; Ryoo BY; Kim KP; Yoo C
Ther Adv Med Oncol; 2020; 12():1758835920923424. PubMed ID: 32523632
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Pusceddu S; Ghidini M; Torchio M; Corti F; Tomasello G; Niger M; Prinzi N; Nichetti F; Coinu A; Di Bartolomeo M; Cabiddu M; Passalacqua R; de Braud F; Petrelli F
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30959763
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness and resource utilization of
Braiteh F; Patel MB; Parisi M; Ni Q; Park S; Faria C
Cancer Manag Res; 2017; 9():141-148. PubMed ID: 28461766
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response.
Nguyen KT; Kalyan A; Beasley HS; Singhi AD; Sun W; Zeh HJ; Normolle D; Bahary N
J Gastrointest Oncol; 2017 Jun; 8(3):556-565. PubMed ID: 28736642
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial.
Huh G; Lee HS; Choi JH; Lee SH; Paik WH; Ryu JK; Kim YT; Bang S; Lee ES
Ther Adv Med Oncol; 2021; 13():17588359211056179. PubMed ID: 34790261
[TBL] [Abstract][Full Text] [Related]
7. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients.
Kieler M; Unseld M; Bianconi D; Schindl M; Kornek GV; Scheithauer W; Prager GW
J Clin Med; 2020 Feb; 9(3):. PubMed ID: 32121198
[TBL] [Abstract][Full Text] [Related]
8. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.
Muranaka T; Kuwatani M; Komatsu Y; Sawada K; Nakatsumi H; Kawamoto Y; Yuki S; Kubota Y; Kubo K; Kawahata S; Kawakubo K; Kawakami H; Sakamoto N
J Gastrointest Oncol; 2017 Jun; 8(3):566-571. PubMed ID: 28736643
[TBL] [Abstract][Full Text] [Related]
9. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine
Chiorean EG; Cheung WY; Giordano G; Kim G; Al-Batran SE
Ther Adv Med Oncol; 2019; 11():1758835919850367. PubMed ID: 31205510
[TBL] [Abstract][Full Text] [Related]
10. Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine.
Di Costanzo F; Di Costanzo F; Antonuzzo L; Mazza E; Giommoni E
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672366
[TBL] [Abstract][Full Text] [Related]
11. Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer.
Kurimoto M; Kimura M; Usami E; Iwai M; Hirose T; Kawachi S; Yoshimura T
Mol Clin Oncol; 2017 Jul; 7(1):125-130. PubMed ID: 28685089
[TBL] [Abstract][Full Text] [Related]
12. Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer.
Kunzmann V; Herrmann K; Bluemel C; Kapp M; Hartlapp I; Steger U
Case Rep Oncol; 2014 Sep; 7(3):648-55. PubMed ID: 25408659
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting.
Cartwright TH; Parisi M; Espirito JL; Wilson TW; Pelletier C; Patel M; Babiker HM
Drugs Real World Outcomes; 2018 Sep; 5(3):149-159. PubMed ID: 29946913
[TBL] [Abstract][Full Text] [Related]
14. Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure.
Mita N; Iwashita T; Uemura S; Yoshida K; Iwasa Y; Ando N; Iwata K; Okuno M; Mukai T; Shimizu M
J Clin Med; 2019 May; 8(6):. PubMed ID: 31146420
[TBL] [Abstract][Full Text] [Related]
15. Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma.
Peddi PF; Cho M; Wang J; Gao F; Wang-Gillam A
J Gastrointest Oncol; 2013 Dec; 4(4):370-3. PubMed ID: 24294508
[TBL] [Abstract][Full Text] [Related]
16. Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study.
Servetto A; Santaniello A; Napolitano F; Foschini F; Marciano R; Mozzillo E; Cascetta P; Amato AR; Augurio MR; Maresca L; De Placido P; De Placido S; Formisano L; Bianco R
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638422
[TBL] [Abstract][Full Text] [Related]
17. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer.
Mie T; Sasaki T; Takeda T; Okamoto T; Hamada T; Ishitsuka T; Yamada M; Nakagawa H; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672308
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of first line FOLFIRINOX
Patel T; Miccio J; Cecchini M; Srikumar T; Stein S; Kortmanksy J; Johung K; Lacy J
J Gastrointest Oncol; 2021 Dec; 12(6):2547-2556. PubMed ID: 35070386
[TBL] [Abstract][Full Text] [Related]
19. FOLFIRINOX
Cho IR; Kang H; Jo JH; Lee HS; Chung MJ; Park JY; Park SW; Song SY; An C; Park MS; Bang S
World J Gastrointest Oncol; 2020 Feb; 12(2):182-194. PubMed ID: 32104549
[TBL] [Abstract][Full Text] [Related]
20. Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience.
Cavanna L; Stroppa EM; Citterio C; Mordenti P; Di Nunzio C; Peveri S; Orlandi E; Vecchia S
Onco Targets Ther; 2019; 12():3077-3085. PubMed ID: 31118666
[No Abstract] [Full Text] [Related]
[Next] [New Search]
